Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.610
0.00 (0.00%)
At close: Apr 2, 2026, 4:00 PM EDT
2.660
+0.050 (1.91%)
After-hours: Apr 2, 2026, 7:49 PM EDT
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Esperion Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.60, which forecasts a 191.19% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $16.
Price Target: $7.60 (+191.19%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +91.57% | Mar 13, 2026 |
| Needham | Needham | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +91.57% | Mar 3, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $9 | Buy | Initiates | $9 | +244.83% | Nov 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +513.03% | Sep 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +513.03% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
414.91M
from 403.14M
Increased by 2.92%
Revenue Next Year
402.60M
from 414.91M
Decreased by -2.97%
EPS This Year
0.14
from -0.11
EPS Next Year
0.22
from 0.14
Increased by 55.99%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 567.3M | 572.5M | |||
| Avg | 414.9M | 402.6M | |||
| Low | 331.0M | 245.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 40.7% | 38.0% | |||
| Avg | 2.9% | -3.0% | |||
| Low | -17.9% | -41.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.61 | 0.85 | |||
| Avg | 0.14 | 0.22 | |||
| Low | -0.31 | -0.78 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 496.1% | |||
| Avg | - | 56.0% | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.